175 related articles for article (PubMed ID: 25695223)
1. Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene.
Kimura M; Endo H; Inoue T; Nishino K; Uchida J; Kumagai T; Kukita Y; Kato K; Imamura F; Inoue M
J Thorac Oncol; 2015 Mar; 10(3):527-30. PubMed ID: 25695223
[TBL] [Abstract][Full Text] [Related]
2. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract][Full Text] [Related]
3. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Endo H; Okami J; Okuyama H; Kumagai T; Uchida J; Kondo J; Takehara T; Nishizawa Y; Imamura F; Higashiyama M; Inoue M
J Thorac Oncol; 2013 Feb; 8(2):131-9. PubMed ID: 23328545
[TBL] [Abstract][Full Text] [Related]
4. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
5. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
[TBL] [Abstract][Full Text] [Related]
6. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
7. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
8. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
9. A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Anai S; Takeshita M; Ando N; Ikematsu Y; Mishima S; Ishida K; Inoue K
J Thorac Oncol; 2016 Oct; 11(10):e126-8. PubMed ID: 27663401
[No Abstract] [Full Text] [Related]
10. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.
Miyazaki R; Anayama T; Hirohashi K; Okada H; Kume M; Orihashi K
PLoS One; 2016; 11(4):e0152665. PubMed ID: 27070423
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
13. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
16. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
[No Abstract] [Full Text] [Related]
17. Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
[TBL] [Abstract][Full Text] [Related]
18. [Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro].
Wu D; Jin G; Zhao D; Zhang Y; Zhao J; Yu H
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):330-9. PubMed ID: 26104888
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.
Kim HR; Kim WS; Choi YJ; Choi CM; Rho JK; Lee JC
Mol Oncol; 2013 Dec; 7(6):1093-102. PubMed ID: 23993685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
